Viking Therapeutics Starts Phase-1 Study with VK3019 – Analysts See Target Price of $93.60

Viking Therapeutics announced on June 24, 2026 the start of a Phase-1 study for the drug candidate VK3019. VK3019 is a dual agonist targeting amylin and calcitonin receptors and is being developed for the treatment of obesity. The San Diego-based company is thereby expanding its pipeline in the growing obesity therapy market.

VK3019: New Approach in the Obesity Market

The drug candidate VK3019 pursues a dual mechanism of action by activating both amylin and calcitonin receptors. These receptors play a central role in regulating appetite and satiety. The Phase-1 study serves to examine the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers – a customary first step in the clinical development of new medications.

Viking Therapeutics is positioning itself with this development in a market segment that has experienced strong growth in recent years. Other companies such as Novo Nordisk and Eli Lilly have already achieved commercial success with GLP-1-based drugs. Viking's approach differs through its focus on amylin and calcitonin receptors.

Existing Pipeline: VK2809 and Additional Candidates

In addition to VK3019, Viking Therapeutics' pipeline comprises several other drug candidates. VK2809, an oral, selective agonist of the thyroid hormone receptor beta (TRß), is in Phase-IIb studies. The company is testing VK2809 for both non-alcoholic steatohepatitis (NASH) – an advanced form of fatty liver disease – as well as non-alcoholic fatty liver disease (NAFLD).

VK5211, an orally available, non-steroidal selective androgen receptor modulator (SARM), is undergoing Phase-II studies for patients recovering from non-elective hip fractures. Additionally, Viking plans to develop VK0612, an oral candidate for type-2 diabetes, which is to enter Phase-IIb studies.

Stock Price and Technical Indicators

On July 2, 2026, Viking Therapeutics' stock closed at $37.44, a decline of 0.11 percent compared to the previous day ($37.48). Trading volume was 10,577 shares. The Relative Strength Index (RSI) stood at 65.03 points on July 1, 2026, after reaching values above 75 at the end of June. An RSI above 70 is technically considered overbought, below 30 as oversold.

According to analyst estimates from July 2, 2026, the average price target is $93.60, with a median price target of $95.00. The range extends from $83.00 (lower target) to $101.00 (upper target). Of 24 analysts, 23 rate the stock as "Buy" or "Strong Buy", with only one analyst recommending "Hold". No sell recommendations exist.

Market Environment and Competition

The obesity therapy market has experienced dynamic development in recent years. The approval and commercial success of GLP-1 receptor agonists have intensified investor and pharmaceutical company interest. Viking Therapeutics is pursuing an alternative mechanism of action with its amylin and calcitonin approach, whose clinical efficacy and tolerability remain to be demonstrated in early study phases.

The company's valuation reflects expectations for its pipeline. With a market capitalization based on the current price of $37.44, the market prices in the opportunities and risks of clinical development. The analyst consensus estimate of $93.60 implies upside potential of approximately 150 percent versus the current price – an indicator of the financial community's positive assessment of the pipeline projects.

Outlook and Next Steps

The Phase-1 study for VK3019 represents the first step in the clinical development of this drug candidate. Results from this early study phase are typically expected within six to twelve months, depending on study design and patient recruitment. Positive data could pave the way for Phase-2 studies, in which efficacy and dosing would be tested in patients with obesity.

Clinical milestones are also ahead for VK2809 and the other pipeline candidates. The development of medications against NASH and NAFLD is considered challenging, as regulatory requirements are high and only a few therapies have been approved to date. Viking Therapeutics must demonstrate both efficacy and safety in the ongoing studies to establish itself in the competitive environment.

Investors in the DACH region monitoring Viking Therapeutics should note that the stock is traded in USD and currency fluctuations play a role. The high analyst rating and the broad price target range illustrate both the potential and the uncertainty associated with biotechnology companies in early development phases.